Protagonist Ther (PTGX) Stock News

Protagonist Therapeutics (NASDAQ:PTGX) has announced the nomination of PN-477, a novel GLP-1, GIP, and GCG receptor triple agonist peptide, as a development candidate for obesity treatment. The drug candidate features both oral (PN-477o) and injectable (PN-477sc) formulations, designed for once-daily and once-weekly administration respectively.

The company reports that PN-477 has demonstrated potent in vitro activity in activating all three targeted receptors and has shown robust preclinical proof-of-concept in various animal studies, including diet-induced obesity mouse models, normal dogs, and cynomolgus monkeys. The candidate is engineered to be orally stable with balanced potencies against the three receptors to potentially maximize weight loss benefits while minimizing adverse effects.

Protagonist has initiated IND-enabling studies and expects to begin Phase 1 clinical trials in the second quarter of 2026. The company positions PN-477 as a potential best-in-class treatment option, aiming to offer weight loss comparable to the best injectable treatments while providing the flexibility of both oral and injectable administration routes.

Protagonist Therapeutics (NASDAQ:PTGX) has scheduled a conference call and webcast for Monday, June 30th at 4:30 pm ET to announce its oral obesity development candidate. The presentation will include details about in vitro and pre-clinical proof-of-concept study results.

Investors can access the call through US dial-in (1-877-407-0752) or international dial-in (1-201-389-0912) using Conference ID 13754335. A webcast replay will be available on the company's Investor Relations webpage after the event.

Protagonist and Takeda announced positive Phase 3 VERIFY study results for rusfertide in treating polycythemia vera (PV), to be presented at ASCO. The study met its primary endpoint with 76.9% of patients on rusfertide plus standard care achieving clinical response vs 32.9% in placebo group. Key findings include a reduction in required phlebotomies (0.5 vs 1.8 per patient) and improved hematocrit control (62.6% vs 14.4% maintaining levels below 45%). The drug showed significant improvements in patient-reported outcomes including fatigue and symptom burden. Rusfertide was well-tolerated with no serious drug-related adverse events, and has received FDA Orphan Drug and Fast Track designations. The treatment represents a potential first-in-class therapy for PV, a condition characterized by red blood cell overproduction that can lead to serious thrombotic events.

Protagonist Therapeutics (PTGX) has announced its participation in the upcoming Jefferies Global Healthcare Conference, scheduled for June 3-5, 2025, in New York. The company's President and CEO, Dinesh V. Patel, Ph.D., will deliver a company overview presentation on Wednesday, June 4, at 1:25 P.M. ET.

The presentation will be available via webcast, and the company will also engage in one-on-one meetings during the conference. Interested parties can access the presentation replay on the Company's Investor Relations Events and Presentations webpage for one year following the event.

Protagonist Therapeutics (PTGX) has presented new clinical data for two key psoriasis treatments at the 2025 SID Annual Meeting. The Phase 3 ICONIC-TOTAL study of icotrokinra, their first-in-class oral IL-23 receptor antagonist, showed significant efficacy in treating difficult-to-treat psoriasis areas. At Week 16, the drug achieved:

- 57% overall skin clearance rate vs 6% for placebo
- 66% scalp psoriasis clearance vs 11% for placebo
- 77% genital psoriasis clearance vs 21% for placebo
- 42% hand/foot psoriasis clearance vs 26% for placebo

The company also presented preclinical data for PN-881, their novel oral IL-17 pathway inhibitor, showing promising potency and stability. PN-881 demonstrated superior potency compared to secukinumab and is scheduled to begin human clinical trials in Q4 2025.

Protagonist Therapeutics (PTGX) reported Q1 2025 financial results and significant clinical progress. The company announced positive Phase 3 VERIFY trial results for rusfertide in polycythemia vera, with data to be presented at ASCO's plenary session on June 1st. Their IL-23 receptor antagonist icotrokinra showed positive results in both Phase 3 ICONIC-LEAD trial for plaque psoriasis and Phase 2b ANTHEM trial for ulcerative colitis. Financially, PTGX reported $697.9M in cash and equivalents, providing runway through 2028, though posted a Q1 net loss of $11.7M ($0.19 per share) compared to prior year's income of $207.3M. License and collaboration revenue decreased to $28.3M from $255.0M in Q1 2024, mainly due to prior year's Takeda collaboration agreement.

Protagonist Therapeutics (PTGX) announced that results from its VERIFY Phase 3 study of Rusfertide for treating Polycythemia Vera (PV) will be presented at the ASCO Annual Meeting Plenary Session. The presentation will be delivered by Dr. Andrew T. Kuykendall from Moffitt Cancer Center on June 1, 2025, at 2:09 PM CDT in McCormick Place, Hall B1.

The VERIFY study is a double-blind, placebo-controlled Phase 3 clinical trial evaluating Rusfertide's effectiveness in PV treatment. The selection for a plenary presentation at ASCO, scheduled for May 30 - June 3, 2025, represents a significant platform for sharing these important clinical findings.

Protagonist Therapeutics (PTGX) has announced the granting of an equity inducement award to a new employee on April 15, 2025. The award, issued under the Company's Amended and Restated 2018 Inducement Plan, consists of options to purchase 20,000 shares of common stock at an exercise price of $46.95 per share, matching the closing price on Nasdaq on the grant date.

The options feature a four-year vesting schedule, with 25% vesting after the first year and the remaining portion vesting in equal monthly installments over the subsequent three years. The award was approved by the Company's Compensation Committee and granted as a material inducement for employment in accordance with Nasdaq Marketplace Rule 5635(c)(4).

Protagonist Therapeutics announced promising Phase 3 trial results for icotrokinra, a first-in-class oral peptide targeting IL-23 receptor for moderate-to-severe plaque psoriasis. The ICONIC-LEAD study's adolescent cohort showed remarkable efficacy at Week 16, with 84.1% achieving clear/almost clear skin (IGA 0/1) and 70.5% reaching PASI 90, compared to 27.3% and 13.6% in placebo group respectively.

Results improved further by Week 24, with 75% of adolescents achieving completely clear skin (IGA 0) and 63.6% reaching PASI 100. The safety profile was favorable, with fewer adverse events in the treatment group (50%) compared to placebo (73%). This marks the first Phase 3 study evaluating a systemic therapy simultaneously in both adolescents and adults with plaque psoriasis.